Medical Questions

ONCONOMICS PLUS, which covers the sensitivity/resistance on conventional & biological/natural substances and CHEMOSNIP which covers the ability of the patients to activate the drugs and metabolize them properly.

Oncocount R.G.C.C. or Oncotrace R.G.C.C. or Oncotrail R.G.C.C. only for known and specific types of malignancies.

For the first year every trimester and then every half year

If a patient asks for additional natural substances to be tested, we can include them in Onconomics Plus or Onconomics Extracts. If additional testing for chemotherapy drugs is required, we are able to include them in the Onconomics test.

The migration from the primary tumor take place relatively early during tumor progression. Almost less than 2mm in diameter the primary tumor already spreads newly form vessels and cells that perform EMT are migrate through them to the circulation.

The isolation of CTCs can be performed with sorting methods based on Flow cytometry and avoid any noise caused by irrelevant cells. The evaluation of CTCs can reveal sensitivity and resistance to several factors in a cellular level. The application to an all organism requires the cooperation and expertise of an oncologist which have very high level of knowledge of pharmacology (Pharmacodynamics and pharmacokinetic) in order to schedule dosages, timing and cycles in a patient level.

Besides the cytotoxic drugs, the monoclonal antibodies or the small molecular weight inhibitors like TKIs, we can test other substances either by a viability/cytotoxicity assay and as induction of the immune response or as inhibitors of growth factor receptors. You can introduce to us any substance you deem fit If you prefer to test these in combination we can offer also that, but it is up to the physician to specify the combination, the timing of each component and the ratio.

The onconomics and onconomics plus test study the expression of specific genes correlated with the efficacy of specific drugs on the cancer cells derived from a single patient.

ChemoSNiP provides information about DNA sequence variations (mutations) that can affect how humans develop disease or respond to chemicals, drugs and other agents.

Every RGCC test can be conducted with blood sample. Only the type of cancer can change this fact. For example, to examine glioblastoma and other types of brain cancer, only tissue is necessary in order to proceed to RGCC tests.

The CGH test provide information about genetic abnormalities (deletions/insertions) on the tumor cells. These abnormalities can be associated with of the primary tumor. This test is quite new. Because of that, it is not yet in our website.

We have many patients with lymphoma or leukemia who have proceeded to RGCC test for CTC count.

If HSP,>=0 (normal), then resistant to hyperthermia or radiation. If HSP is less than 0, then sensitive to hyperthermia or radiation.

Regarding the ABG2 pumps, the patient could proceed as first choice with Ketoconazole and as second choice with Verapanib (the last one contributes to the drop of blood pressure).

The RGCC analytics present negative CTC results (Negative Predictive Value – NPV) at about 86.2%.

There are not viable cells once the tissue is placed in formalin. In order to maintain the cells viable you should place the tissue in the appropriate tissue vial that we provide. In case of the sample can be fixated and a paraffin block can be produced (F.F.P.E tissue) then DNA and/or RNA can be isolated. Therefore only tests correlated with DNA/RNA study (ChemoSnip, CGH, Gene expression-RT PCR) could be performed.

If the patient needs to order only ChemoSNiP then he might use swab, but, if she/he wishes to order also another test with the ChemoSNiP, DNA will be isolated from the blood, so there is no need to use swab.

CTCs number is calculated in correlation with the blood total cells (× CTCs per ml). In a sample material which is tissue, CTCs number cannot be adjusted proportional. In order to proceed with any test, we need a blood sample. Tissue sample is only necessary and used when the patient has brain tumor, such cancer cells cannot be detected in blood sample due to blood-brain-barrier.

The main cells of interest in analytic platform are CTCs which are obtained by negative selection and sorting via flow cytometer (so that we will obtain viable CTCs from a blood sample). Further information can be obtained through our web site.

For all solid and hematologic malignancies with exception of primary tumor of the CNS.

In one type of cancer there are several subpopulation of cancer cells but only one has the tumor initiating properties (known as cancer stem cells like) . The rest subset does not actually promote the disease progression. So this is the population that were interested to harvest and analyze and this subset exist in higher proportion in CTCs.

R.G.C.C. FAQ Database